Cart
sales@molnova.com
PF-184298
CAS No. 813447-40-4
PF-184298( —— )
Catalog No. M34376 CAS No. 813447-40-4
PF-184298 is a serotonin and norepinephrine monoamine reuptake inhibitor (SNRI) that inhibits dopamine reuptake.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF-184298
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-184298 is a serotonin and norepinephrine monoamine reuptake inhibitor (SNRI) that inhibits dopamine reuptake.
-
DescriptionPF-184298 is a dual serotonin/noradrenaline reuptake inhibitor with IC50 of 6 nM and 21 nM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor | Dopamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number813447-40-4
-
Formula Weight315.24
-
Molecular FormulaC15H20Cl2N2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1=C(Cl)C(Cl)=CC=C1)(CC(C)C)[C@H]2CCNC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anthony Harrison , et al. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Clinical Trial Xenobiotica. 2012 Jan;42(1):57-74.?
molnova catalog
related products
-
3-Hydroxy agomelatin...
3-Hydroxy agomelatine is an Agomelatine metabolite and a 5-HT2C receptor antagonist (IC50: 3.2 μM; Ki: 1.8 μM).
-
Setiptiline maleate
A tetracyclic antidepressant (TeCA) that acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist.
-
ST1936
ST1936 (ST 1936 oxalate) is a selective and highly potent 5-HT6 receptor agonist that inhibits human 5-HT6, 5-HT7 and 5-HT2B receptors by fully activating cloned human 5-HT6 receptors.
